Formulation & Development Of Buccal Tablets For Losinopril: A Novel Approach For Migraine Management

Migraine is a debilitating neurological disorder characterized by recurrent severe headaches.Current oral treatments often suffer from slow onset of action and potential gastrointestinal side effects.This research explores the formulation and development of buccal tablets containing lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, as a novel approach for rapid and effective migraine management.Lisinopril's potential to modulate the renin-angiotensin system, implicated in migraine pathophysiology, makes it a promising candidate.Buccal delivery offers advantages such as bypassing first-pass metabolism, rapid absorption, and improved patient compliance.This study investigates the influence of different polymers on the mucoadhesive properties, drug release profile, and overall performance of lisinopril buccal tablets.